ANTITROMBOTIC ACTIVITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH A SPATIALLY DIFFICULT PHENOLIC SUBSTITUTE IN ITS STRUCTURE

The aim of the study was to investigate antithrombogenic properties of compound RU-1144 with previously identified pronounced antiplatelet and antioxidant activities. The thrombosis induced by Ferric chloride (FeCl3) was carried out in rats’ carotid artery, in comparison with the known antiaggregant...

Full description

Bibliographic Details
Main Authors: Alexander A. Spasov, Aida F. Kucheryavenko, Ksenia A. Gaidukova, Maxim V. Chernikov, Olga N. Zhukovskaya
Format: Article
Language:Russian
Published: Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2020-10-01
Series:Фармация и фармакология (Пятигорск)
Subjects:
Online Access:https://www.pharmpharm.ru/jour/article/view/685
_version_ 1797874706874892288
author Alexander A. Spasov
Aida F. Kucheryavenko
Ksenia A. Gaidukova
Maxim V. Chernikov
Olga N. Zhukovskaya
author_facet Alexander A. Spasov
Aida F. Kucheryavenko
Ksenia A. Gaidukova
Maxim V. Chernikov
Olga N. Zhukovskaya
author_sort Alexander A. Spasov
collection DOAJ
description The aim of the study was to investigate antithrombogenic properties of compound RU-1144 with previously identified pronounced antiplatelet and antioxidant activities. The thrombosis induced by Ferric chloride (FeCl3) was carried out in rats’ carotid artery, in comparison with the known antiaggregant drugs - acetylsalicylic acid (ASA) and clopidogrel, as well as with the antioxidant preparation - ethylmethylhydroxypyridine succinate (EMHPS).Materials and methods. The antithrombotic activity of compound RU-1144 was studied on the model of the rats with carotid artery thrombosis, induced by the application of 50% ferric chloride (FeCl3), and the Global Thrombosis Test model (the Görög Thrombosis Test). The evaluation of this type of activity was carried out by prolonging the time of a blood clot formation. The studies of the compound RU-1144 effect on the bleeding time parameter were performed in mice. Acetylsalicylic acid, clopidogrel and EMHPS were used as reference drugs.Results. The antithrombotic effect of the RU-1144 substance revealed in the model of arterial thrombosis induced by the application of ferric chloride (FeCl3), exceeded that of both acetylsalicylic acid and clopidogrel by 3.5 times and that of EMHPS by 2.9 times. In the model of the in vitro Global Thrombosis Test (the Görög Thrombosis Test), compound RU-1144 reduced the thrombogenic potential of the blood equally with acetylsalicylic acid and clopidogrel. The assessment of “the bleeding time”, caused by the RU-1144 substance, showed that the prolongation of bleeding was twice as less pronounced than that caused by ASA and clopidogrel.Conclusion. The performed studies demonstrated a pronounced antithrombotic activity of compound RU-1144, which exceeded that of acetylsalicylic acid, clopidogrel and EMHPS, while the ability to prolong the bleeding time was reliably lower than that of reference drugs.Abbreviations: EMHPS-ethylmethylhydroxypyridine succinate; ASA - acetylsalicylic acid.
first_indexed 2024-04-10T01:36:16Z
format Article
id doaj.art-c0a7ad2a433448b59f793fd1bba325d6
institution Directory Open Access Journal
issn 2307-9266
2413-2241
language Russian
last_indexed 2024-04-10T01:36:16Z
publishDate 2020-10-01
publisher Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
record_format Article
series Фармация и фармакология (Пятигорск)
spelling doaj.art-c0a7ad2a433448b59f793fd1bba325d62023-03-13T09:18:12ZrusVolgograd State Medical University, Pyatigorsk Medical and Pharmaceutical InstituteФармация и фармакология (Пятигорск)2307-92662413-22412020-10-0182788510.19163/2307-9266-2020-8-2-78-85335ANTITROMBOTIC ACTIVITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH A SPATIALLY DIFFICULT PHENOLIC SUBSTITUTE IN ITS STRUCTUREAlexander A. Spasov0Aida F. Kucheryavenko1Ksenia A. Gaidukova2Maxim V. Chernikov3Olga N. Zhukovskaya4Волгоградский государственный медицинский университетВолгоградский государственный медицинский университетВолгоградский государственный медицинский университетПятигорский медико-фармацевтический институт - филиал ВолгГМУНИИ физической и органической химии Южного федерального университетаThe aim of the study was to investigate antithrombogenic properties of compound RU-1144 with previously identified pronounced antiplatelet and antioxidant activities. The thrombosis induced by Ferric chloride (FeCl3) was carried out in rats’ carotid artery, in comparison with the known antiaggregant drugs - acetylsalicylic acid (ASA) and clopidogrel, as well as with the antioxidant preparation - ethylmethylhydroxypyridine succinate (EMHPS).Materials and methods. The antithrombotic activity of compound RU-1144 was studied on the model of the rats with carotid artery thrombosis, induced by the application of 50% ferric chloride (FeCl3), and the Global Thrombosis Test model (the Görög Thrombosis Test). The evaluation of this type of activity was carried out by prolonging the time of a blood clot formation. The studies of the compound RU-1144 effect on the bleeding time parameter were performed in mice. Acetylsalicylic acid, clopidogrel and EMHPS were used as reference drugs.Results. The antithrombotic effect of the RU-1144 substance revealed in the model of arterial thrombosis induced by the application of ferric chloride (FeCl3), exceeded that of both acetylsalicylic acid and clopidogrel by 3.5 times and that of EMHPS by 2.9 times. In the model of the in vitro Global Thrombosis Test (the Görög Thrombosis Test), compound RU-1144 reduced the thrombogenic potential of the blood equally with acetylsalicylic acid and clopidogrel. The assessment of “the bleeding time”, caused by the RU-1144 substance, showed that the prolongation of bleeding was twice as less pronounced than that caused by ASA and clopidogrel.Conclusion. The performed studies demonstrated a pronounced antithrombotic activity of compound RU-1144, which exceeded that of acetylsalicylic acid, clopidogrel and EMHPS, while the ability to prolong the bleeding time was reliably lower than that of reference drugs.Abbreviations: EMHPS-ethylmethylhydroxypyridine succinate; ASA - acetylsalicylic acid.https://www.pharmpharm.ru/jour/article/view/685антитромботическая активностьтромбозбензимидазоласкклопидогрелэтилметилгидрокси- пиридина сукцинаттромбоз по горогувремя кровотечения
spellingShingle Alexander A. Spasov
Aida F. Kucheryavenko
Ksenia A. Gaidukova
Maxim V. Chernikov
Olga N. Zhukovskaya
ANTITROMBOTIC ACTIVITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH A SPATIALLY DIFFICULT PHENOLIC SUBSTITUTE IN ITS STRUCTURE
Фармация и фармакология (Пятигорск)
антитромботическая активность
тромбоз
бензимидазол
аск
клопидогрел
этилметилгидрокси- пиридина сукцинат
тромбоз по горогу
время кровотечения
title ANTITROMBOTIC ACTIVITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH A SPATIALLY DIFFICULT PHENOLIC SUBSTITUTE IN ITS STRUCTURE
title_full ANTITROMBOTIC ACTIVITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH A SPATIALLY DIFFICULT PHENOLIC SUBSTITUTE IN ITS STRUCTURE
title_fullStr ANTITROMBOTIC ACTIVITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH A SPATIALLY DIFFICULT PHENOLIC SUBSTITUTE IN ITS STRUCTURE
title_full_unstemmed ANTITROMBOTIC ACTIVITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH A SPATIALLY DIFFICULT PHENOLIC SUBSTITUTE IN ITS STRUCTURE
title_short ANTITROMBOTIC ACTIVITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH A SPATIALLY DIFFICULT PHENOLIC SUBSTITUTE IN ITS STRUCTURE
title_sort antitrombotic activity of a new benzimidazole derivative with a spatially difficult phenolic substitute in its structure
topic антитромботическая активность
тромбоз
бензимидазол
аск
клопидогрел
этилметилгидрокси- пиридина сукцинат
тромбоз по горогу
время кровотечения
url https://www.pharmpharm.ru/jour/article/view/685
work_keys_str_mv AT alexanderaspasov antitromboticactivityofanewbenzimidazolederivativewithaspatiallydifficultphenolicsubstituteinitsstructure
AT aidafkucheryavenko antitromboticactivityofanewbenzimidazolederivativewithaspatiallydifficultphenolicsubstituteinitsstructure
AT kseniaagaidukova antitromboticactivityofanewbenzimidazolederivativewithaspatiallydifficultphenolicsubstituteinitsstructure
AT maximvchernikov antitromboticactivityofanewbenzimidazolederivativewithaspatiallydifficultphenolicsubstituteinitsstructure
AT olganzhukovskaya antitromboticactivityofanewbenzimidazolederivativewithaspatiallydifficultphenolicsubstituteinitsstructure